These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 20090429

  • 1. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S, Arora RR.
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 7. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M.
    Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 06; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 11. [Renin-angiotensin system modulation: instructions for use].
    Bellis A, Rozza F, Crispo S, Trimarco B.
    G Ital Cardiol (Rome); 2008 Feb 06; 9(2):79-89. PubMed ID: 18383770
    [Abstract] [Full Text] [Related]

  • 12. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P.
    Vnitr Lek; 2006 Sep 06; 52(9):791-6. PubMed ID: 17091602
    [Abstract] [Full Text] [Related]

  • 13. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 14. RAS inhibition in hypertension.
    Ibrahim MM.
    J Hum Hypertens; 2006 Feb 06; 20(2):101-8. PubMed ID: 16397519
    [Abstract] [Full Text] [Related]

  • 15. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R, Brown DL.
    Am J Cardiol; 2007 Apr 01; 99(7):1006-12. PubMed ID: 17398202
    [Abstract] [Full Text] [Related]

  • 16. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep 01; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC, MacDonald TM.
    Int J Clin Pract; 1998 Oct 01; 52(7):475-81. PubMed ID: 10622089
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan 01; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 19. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar 01; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 20. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT.
    J Am Board Fam Med; 2009 Mar 01; 22(6):686-97. PubMed ID: 19897698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.